|
Name |
2-Methyl-1H-pyrrole
|
Molecular Formula | C5H7N | |
IUPAC Name* |
2-methyl-1H-pyrrole
|
|
SMILES |
CC1=CC=CN1
|
|
InChI |
InChI=1S/C5H7N/c1-5-3-2-4-6-5/h2-4,6H,1H3
|
|
InChIKey |
TVCXVUHHCUYLGX-UHFFFAOYSA-N
|
|
Synonyms |
2-Methyl-1H-pyrrole; 636-41-9; 2-METHYLPYRROLE; 1H-Pyrrole, 2-methyl-; Pyrrole, 2-methyl-; alpha-Methylpyrrole; 2-Methylpyrolle; .alpha.-Methylpyrrole; MFCD02822910; NSC-81346; 486RY4814O; a-Methylpyrrole; UNII-486RY4814O; 2-Methyl pyrrole; 2-Methyl-Pyrrole; (2-pyrryl)methane; NSC81346; alpha -methylpyrrole; EINECS 211-255-4; NSC 81346; 2-methyl-1H-pyrazole; 2-Methyl-1H-pyrrole #; Pyrrole, 2-methyl- (8CI); DTXSID70212976; CHEBI:193616; 1H-Pyrrole, 2-methyl- (9CI); AMY18997; ZINC1574399; AKOS006221233; AB12705; CS-W011360; DA-25958; SY004787; FT-0762789; EN300-49636; 93M981; A868079; Q27259111; Z594218440
|
|
CAS | 636-41-9 | |
PubChem CID | 12489 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 81.12 | ALogp: | 1.1 |
HBD: | 1 | HBA: | 0 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 15.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 6 | QED Weighted: | 0.49 |
Caco-2 Permeability: | -4.22 | MDCK Permeability: | 0.00002760 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.128 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.948 | Plasma Protein Binding (PPB): | 48.01% |
Volume Distribution (VD): | 2.103 | Fu: | 63.35% |
CYP1A2-inhibitor: | 0.55 | CYP1A2-substrate: | 0.678 |
CYP2C19-inhibitor: | 0.236 | CYP2C19-substrate: | 0.459 |
CYP2C9-inhibitor: | 0.024 | CYP2C9-substrate: | 0.764 |
CYP2D6-inhibitor: | 0.168 | CYP2D6-substrate: | 0.706 |
CYP3A4-inhibitor: | 0.019 | CYP3A4-substrate: | 0.207 |
Clearance (CL): | 10.247 | Half-life (T1/2): | 0.847 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.391 |
Drug-inuced Liver Injury (DILI): | 0.086 | AMES Toxicity: | 0.056 |
Rat Oral Acute Toxicity: | 0.949 | Maximum Recommended Daily Dose: | 0.07 |
Skin Sensitization: | 0.625 | Carcinogencity: | 0.151 |
Eye Corrosion: | 0.953 | Eye Irritation: | 0.993 |
Respiratory Toxicity: | 0.972 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000439 | 0.393 | D0S4BR | 0.241 | ||||
ENC005078 | 0.279 | D02NJA | 0.214 | ||||
ENC000178 | 0.278 | D0U3DU | 0.204 | ||||
ENC000064 | 0.276 | D0T3LF | 0.184 | ||||
ENC000028 | 0.258 | D05BMG | 0.184 | ||||
ENC001061 | 0.258 | D0X0RI | 0.182 | ||||
ENC000179 | 0.258 | D06GIP | 0.179 | ||||
ENC000240 | 0.258 | D0X7NU | 0.179 | ||||
ENC000239 | 0.258 | D03GET | 0.178 | ||||
ENC000041 | 0.257 | D05OIS | 0.176 |